Monosodium Iodoacetate-Induced Joint Pain and MAPK Activation in Rats
Author Information
Author(s): Lee Younglim, Pai Madhavi, Brederson Jill-Desiree, Wilcox Denise, Hsieh Gin, Jarvis Michael F, Bitner Robert S
Primary Institution: Abbott Laboratories
Hypothesis
The study investigates the role of MAPK activation in central sensitization associated with joint pain induced by monosodium iodoacetate in rats.
Conclusion
The study found that MAPK activation is involved in the progression and maintenance of central sensitization in a rat model of osteoarthritis pain.
Supporting Evidence
- MIA-injected rats showed reduced hind limb grip force at 1, 2, and 3 weeks post-treatment.
- Phosphorylation of ERK1/2 increased significantly by week 3 post-MIA injection.
- Phosphorylation of p38 MAPK was maximal at week 1 and decreased thereafter but remained elevated.
- Mechanical allodynia was observed in the contralateral hind limb 3 weeks after MIA injection.
- Intrathecal injection of a MEK1 inhibitor blocked the reduction in grip force and pERK1/2 induction.
Takeaway
Researchers gave rats a chemical that causes joint pain and found that certain proteins in their spinal cords became more active, which is linked to pain.
Methodology
The study used a rat model where monosodium iodoacetate was injected into the knee joint, followed by behavioral and immunohistochemical assessments of pain and MAPK activation.
Limitations
The study primarily focused on a single animal model and may not fully represent human osteoarthritis.
Participant Demographics
Adult male Sprague-Dawley rats (250-300 g)
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website